sees fy adjusted earnings per share $5.09 to $519.00.
sees fy adjusted net income $2.415 billion to $2,470 billion.
sees fy revenue $8.325 billion to $8475 billion.
qtrly revenue rose 9 percent to $2.2 billion.
qtrly livestock business declined 6% as a result of generic competition for draxxin unfavorable market conditions in u.s.
qtrly u.s. international sales grew 17% versus prior year.
qtrly revenue of $7.8 billion and adjusted net income of $2.2 billion both exceeded high end of november 2021 guidance range.
qtrly revenue of $124 million versus refinitiv ibes estimate of $100 million.
qtrly u.s. livestock sales decreased 13%.
qtrly revenue increased 15% to $15 billion.
qtrly u.s. livestock revenue fell 13% to $1.1 billion.
sees fy revenue up 9% to 11% from prior year.
q4 revenue rose 23 percent to $316 million.
qtrly adjusted net income increased 19 percent to $19.2 million.
qtrly adjusted net income increased 21% on a reported basis and 19% on an operating basis.
qtrly sales of simparica trio were $425 million versus refinitiv ibes estimate of $305 million.
